White label ELPA - ClinicalTrials.eu

Study on PRAX-562 for Children with Developmental and Epileptic Encephalopathies

Not recruiting

2 1
Investigated diseases:
- Epileptic encephalopathy
Study on Hydroxycarbamide Resistance in Patients with Polycythemia Vera Identified by AI Predictors

Not recruiting

3 1 1 1
Investigated diseases:
- Polycythaemia vera
Investigated drugs:
- Hydroxycarbamide
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Not recruiting

3 1
Investigated diseases:
- Colitis ulcerative
Investigated drugs:
- Obefazimod
+8
Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Not recruiting

4 1
Investigated diseases:
- Hidradenitis
Investigated drugs:
- Spesolimab
+11
Study on Detecting Early Barrett’s Esophagus Using Bevacizumab-800CW and Cetuximab-800CW for Patients with Barrett’s Esophagus

Not recruiting

2 1 1 1
Investigated diseases:
- Barrett’s oesophagus
Investigated drugs:
- Bevacizumab
- Cetuximab
Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis

Not recruiting

2 1 1 1
Investigated diseases:
- Portal hypertension
Investigated drugs:
- Bi 685509
- Empagliflozin
+3
Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

Not recruiting

3 1 1
Investigated diseases:
- Neoplasm malignant
Investigated drugs:
- Darolutamide
+11
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Not recruiting

3 1
Investigated diseases:
- Colitis ulcerative
Investigated drugs:
- Obefazimod
+7
Study on the Effects of Tasipimidine for Patients with Insomnia Disorder

Not recruiting

2 1
Investigated diseases:
- Insomnia
Investigated drugs:
- Tasipimidine
Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Not recruiting

2 1 1 1
Investigated diseases:
- Neoplasm
Investigated drugs:

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies